Pharmaceuticals, Biotechnology and Life Sciences
HighTide Therapeutics said that its HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes, as HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk factors.
Enanta’s study has met its primary endpoint, as ALT reduction at week 12, was met in the 2.5mg dosing group in testing its lead FXR agonist, EDP-305 for treatment of NASH, also meeting key secondary endpoint, reduction in liver fat content as measured by MRI-PDFF at week 12, in the 2.5mg dosing group.
Novartis and Allergan have joined forces to conduct a Phase IIb study to test combination of a Novartis FXR agonist and Allergan’s cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH).